| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.67▼ | 1.68▼ | 1.66▼ | 1.57▲ | 1.63▲ |
| MA10 | 1.68▼ | 1.67▼ | 1.67▼ | 1.53▲ | 1.39▲ |
| MA20 | 1.67▼ | 1.68▼ | 1.64▲ | 1.56▲ | 1.29▲ |
| MA50 | 1.68▼ | 1.59▲ | 1.53▲ | 1.37▲ | 2.18▼ |
| MA100 | 1.62▲ | 1.54▲ | 1.51▲ | 1.29▲ | 3.17▼ |
| MA200 | 1.54▲ | 1.54▲ | 1.52▲ | 1.81▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.007▼ | -0.005▼ | 0.004▲ | 0.120▲ |
| RSI | 41.093▼ | 50.481▲ | 58.426▲ | 58.916▲ | 51.800▲ |
| STOCH | 60.000 | 45.000 | 41.003 | 58.552 | 56.116 |
| WILL %R | -100.000▼ | -80.000▼ | -53.333 | -23.171▲ | -43.522 |
| CCI | -111.111▼ | -103.876▼ | -21.351 | 184.554▲ | 86.728 |
|
Thursday, August 14, 2025 05:13 AM
In the second quarter of 2025, Zura Bio initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe HS. A topline data readout is anticipated in the ...
|
|
Monday, August 11, 2025 09:36 AM
Novartis (NVS) on Monday announced positive results from its late-stage trials evaluating its investigational drug Ianalumab in adults with active Sjögren's disease. Ianalumab is a novel fully human ...
|
|
Thursday, July 17, 2025 06:31 AM
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 1.73 | 1.755 | 1.64 | 1.66 | 470,900 |
| 14/08/25 | 1.57 | 1.74 | 1.57 | 1.72 | 374,271 |
| 13/08/25 | 1.50 | 1.64 | 1.47 | 1.59 | 390,800 |
| 12/08/25 | 1.39 | 1.49 | 1.39 | 1.47 | 145,410 |
| 11/08/25 | 1.50 | 1.52 | 1.39 | 1.41 | 640,431 |
| 08/08/25 | 1.49 | 1.4999 | 1.41 | 1.42 | 232,418 |
| 07/08/25 | 1.52 | 1.555 | 1.47 | 1.48 | 170,900 |
| 06/08/25 | 1.58 | 1.58 | 1.4701 | 1.52 | 231,465 |
| 05/08/25 | 1.46 | 1.61 | 1.445 | 1.57 | 410,609 |
| 04/08/25 | 1.50 | 1.5494 | 1.45 | 1.46 | 345,920 |
|
|
||||
|
|
||||
|
|